Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagmokitug + pasritamig
- Lead developer
- Coherus BioSciences
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
tagmokitug + pasritamig is an investigational combination of two immunotherapies being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Tagmokitug (formerly CHS-114 or SRF-114) is a highly selective, cytolytic, afucosylated human IgG1 monoclonal antibody developed by Coherus BioSciences that targets C-C motif chemokine receptor 8 (CCR8) to preferentially deplete immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment. Pasritamig (formerly JNJ-78278343) is a first-in-class T-cell-redirecting bispecific antibody developed by Johnson & Johnson that simultaneously binds human kallikrein-related peptidase 2 (KLK2) on prostate cancer cells and the CD3 receptor complex on T cells. Under a clinical supply agreement established in February 2026, Coherus sponsors a Phase 1b study of the combination in patients with mCRPC, with Johnson & Johnson supplying pasritamig.
- Other names
- CHS-114 + JNJ-78278343CHS-114 + pasritamigtagmokitug + JNJ-78278343tagmokitug and pasritamig
02
Targets
Beyond the preview
Go deeper on tagmokitug + pasritamig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagmokitug + pasritamig.
Work on tagmokitug + pasritamig? Claim this page to correct or add information. Claim this page